Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study

DOI Web Site 1 Citations

Mark H Einstein

Montefiore Medical Center; Albert Einstein College of Medicine; Department of Obstetrics & Gynecology and Women's Health; Bronx, NY USA
Myron J Levin

University of Colorado Denver and Health Sciences Center; Aurora, CO USA
Archana Chatterjee

University of South Dakota; Sanford School of Medicine and Sanford Children's Specialty Clinics; Sioux Falls, SD USA
Nahida Chakhtoura

University of Miami; Miami, FL USA
Peter Takacs

University of Miami; Miami, FL USA
Grégory Catteau

GlaxoSmithKline Vaccines; Belgium
Francis J Dessy

GlaxoSmithKline Vaccines; Belgium
Philippe Moris

GlaxoSmithKline Vaccines; Belgium
Lan Lin

XPE Pharma & Science, Wavre, Belgium, on behalf of GlaxoSmithKline Vaccines
Frank Struyf

GlaxoSmithKline Vaccines; Belgium
Gary Dubin

GlaxoSmithKline Vaccines; King of Prussia, PA USA

Journal

Human Vaccines & Immunotherapeutics

Human Vaccines & Immunotherapeutics 10 (12), 3455-3465, 2014-11

Informa UK Limited

Back to top